Six New Weight-Loss Drugs Move Through Trials
Adults seeking weight-loss treatment may see more options in coming years, though none of these candidates are yet approved.
Updated on Nov. 2, 2026 in Weight Loss

Live Poll
Would you support wider access to new weight-loss drugs if they were approved?
Multiple pharmaceutical companies are developing six new weight-loss drugs, following the rapid rise of GLP-1 medications. Several candidates are in late-stage trials, and some have reported substantial average weight loss in clinical studies, though none have approval.
Why it matters
The GLP-1 boom has pushed many drugmakers into obesity research, which could widen the range of treatment options for adults managing weight. Because these candidates remain in trials, their future availability, cost, and safety profiles are not yet established.
The figures come from clinical trials of several candidate drugs at different stages, with reported average weight loss ranging from about 10.7% to 20% of body weight. These are trial results rather than confirmed real-world outcomes, and comparator details are limited in the source.
The players
Eli Lilly
A major drugmaker known for its diabetes and obesity treatments, developing EloraTZP, Foundayo, and retatrutide.
Novo Nordisk
A Danish drugmaker known for its GLP-1 diabetes and obesity medications, developing Amycretin and Cagrisema.
Amgen
A biotechnology company developing MariTide, which is being tested in six late-stage trials for obesity and related conditions.
Roche
A Swiss pharmaceutical company developing enicepatide, a dual-acting drug targeting obesity and Type 2 diabetes.
Pfizer
A global pharmaceutical company developing PF-3944, an experimental weight-loss drug.
The details
MariTide, developed by Amgen, blocks GIP receptors, while a separate peptide in the pipeline activates GLP-1 receptors. Roche's enicepatide is a dual-acting drug designed to address both obesity and Type 2 diabetes. Several candidates are being tested across multiple late-stage trials that cover obesity and related conditions.
Timeline
January: A study reported that MariTide's weight loss was maintained even with less frequent dosing.
Early 2027: Two late-stage Roche enicepatide trials are pending, including a glycemic control study and a cardiovascular study.
Health Landscape
The surge in GLP-1 medications has prompted a broader pipeline of obesity drugs from multiple companies, moving beyond the first-generation treatments. These new candidates aim to offer different mechanisms and combination approaches, though most remain in trials.
If you are managing weight, these candidates signal that more treatment options may arrive in the coming years, though none are available yet. It is worth discussing with your doctor which currently approved options may fit your situation and what to expect from them.
The takeaway
The expanding pipeline suggests the obesity drug field is maturing beyond a single drug class. Readers tracking this space can watch for trial results and regulatory updates, and should bring questions about any approved options to their physician.
What happens next
Two late-stage Roche enicepatide trials, a glycemic control study and a cardiovascular study, are pending in early 2027.
Further reading
For background on how these newer candidates fit into the broader field, explore our Weight Loss coverage.
Source note: This article includes information reported by NewsNation.
Live Poll
Would you support wider access to new weight-loss drugs if they were approved?


